マウスにおけるカシェキアの誘発は,全身的に投与されたミオスタチンによるものです

Teresa A Zimmers¹, Monique V Davies, Leonidas G Koniaris

¹Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.

Science (New York, N.Y.)

|May 25, 2002

まとめ

ミオスタチンは通常,筋肉の成長を抑制します. 成人マウスの場合,ミオスタチンは全身的に作用し,筋肉と脂肪の損失を引き起こし,筋肉の消耗状態の治療の標的となる可能性があります.

科学分野:

バイオケミストリーバイオケミストリー
生理学生理学とは
遺伝学遺伝学とは

背景:

ミオスタチンの遺伝的欠乏は,マウスと牛の骨格筋量増加につながります.
ミオスタチンは,筋肉成長の抑制剤として知られています.
筋肉量に対するミオスタチンの効果 (産前 vs 産後) のタイミングは不明である.

研究の目的:

成人動物におけるミオスタチンの全身的役割を調査する.
成人マウスのミオスタチン活性が調節できるかどうかを判断する.
ミオスタチンを筋肉消耗状態の潜在的な治療標的として調査する.

主な方法:

成人マウスにおけるミオスタチンの循環形態と活性化の評価.
成人マウスにおける全身性ミオスタチンの過剰発現を誘導する.
ミオスタチンの過剰発現が筋肉と脂肪に与える影響を観察した.

主要な成果:

ミオスタチンは成人マウスの体内に潜伏状態で循環し,酸によって活性化されます.
成人マウスにおける全身性ミオスタチンの過剰発現は,重要な筋肉と脂肪の損失を引き起こした.
観察された効果は,人間のカシェキア症候群を模倣した.

結論:

ミオスタチンは,成年動物の体内全体に作用する.
ミオスタチンは,出生後の筋肉と脂肪の重要な調節剤です.
ミオスタチンは,カチェキアなどの筋肉喪失を含む状態のための潜在的な薬理学的標的を提示します.

さらに関連する動画

02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

関連する概念動画

01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...

00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...

01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...

関連する実験動画